Juan De Borbon – Introducing state-of-the-art techniques to the healthcare industry

Hispanic American Clinical Research Framework John of Bourbon resides in the United States. He has extensive experience in managing nearly 2000 clinical trials in various therapeutic areas. These include cancer, nephrology, hepatology, infectious diseases (Covid-19, Ebola, Marburg, influenza, HIV, hepatitis) and neurology. Juan de Borbón has been inspiring and motivating the clinical drug development sector for over 20 years using his deep industry knowledge.

Alfonso XIII of Spain’s eldest great-grandson, Juan de Borbón, is his direct matrilineal descendant. King Alfonso XIII of Spain and his wife, Princess Victoria Eugenie of Battenberg, had a son, Alfonso, the eldest of five siblings. Alfonso, Prince of Asturias, who lived from May 10, 1907, to September 6, 1938, was the heir apparent to the Spanish crown and Juan’s grandfather. At the time, Alfonso’s renunciation and untimely death as heir to the Spanish monarchy sparked debate. King Felipe VI of Spain, his cousin, now sits on the throne of Spain.

At the age of two months, Juan de Borbón immigrated to the United States and spent his formative years in Los Angeles. Growing up, he practiced martial arts, surfed, skateboarded, and shared a deep passion for baseball with his father. His parents wanted him to have a wider variety of experiences and a deeper appreciation of his roots. Today, he is a top CEO honored for his achievements and model leadership by the company, his employers and his colleagues; Juan now serves as Director and President of Global Strategy at Global Earth USA, Executive Chairman of Borbon d’Anjou Holdings, and Director of the Borbon Family Office.

He is a compassionate leader who upholds the principles of integrity, honesty and creativity, working directly with Nano Cures Pharma in 2021 to provide Covid-19 vaccines to underserved countries – now working with Thailand and the Central African Republic to obtain emergency use authorization for vaccination in these countries.

Juan de Borbón established America’s first cardiac training center at a clinical pharmacology facility in 2017, ensuring the highest level of acute care staff training for research participants. It combined WCCT with Medelis, an institution that conducts clinical research in oncology, in 2016. The deal covered the complex and growing industry of oncology drug development in the United States, Europe and Asia. It requires a unique response with knowledge, insight and a focus on the future.

With a focus on oncology, ophthalmology, gastroenterology, gastrointestinal, nephrology, liver and virology, Juan de Borbón created in 2014 a multi-site management service offering CRO services for WCCT. This service provided data processing, statistics, medical monitoring, drug safety, tracking, site selection and site management. He established the first clinical research facilities for cosmetology and ophthalmology in 2013 and combined OC Clinical Trials & Consulting with WCCT Global.

Juan thinks that the era of regular health activities is over. Despite the tireless efforts of well-meaning and well-trained professionals, every healthcare system around the world is grappling with rising prices and uneven quality. Healthcare leaders and decision-makers have attempted to fight fraud, reduce errors, enforce practice guidelines, improve patient “consumers,” and deploy electronic medical records. Yet none of them had much of an impact. It’s time to take a completely different approach.

It focuses on the shift from a supply-driven, physician-centered health system to a patient-centered, patient-centered system organized around patient needs. A system where services for specific medical conditions are concentrated in health care delivery organizations and in appropriate locations to provide high value care must be put in place to replace today’s fragmented system, in which each local provider offers a wide range of services. The volume and financial success of the services provided – doctor visits, hospital stays, operations and tests – must be geared towards the success of patient outcomes.

Juan aims to launch the world’s first medical metropolis to promote longevity and good health while using information and communication technologies for the exchange of reliable data for the evaluation, care and prevention of disease and injury, research and evaluation, and for the continuing education of health professionals, all to improve the health of people and their communities. In addition, it is intended to help the patient maintain their level of performance throughout their life. The main risk factor for most diseases is advancing age, especially of cellular structures, and the life expectancy of the population continues to increase.

Juan points out that the state-of-the-art Longevity Center offers tailored preventative medicine by implementing methods to promote healthy aging, delay diseases primarily related to aging, and extend a person’s active lifespan. Vendors that continue to use today’s outdated methods will disappear. Reputations based on perception rather than actual results will deteriorate. In the face of increased openness and lower reimbursement levels, it will be impossible to maintain current cost structures and prices. The only reputation that should matter in healthcare is helping people lead the healthiest, most sustainable lives possible.

Did you read?
Largest economies in the world, 2022.
Ranking of international financial centers, 2022.
These are the countries with the highest average salaries, 2022.
CEO Spotlight: For Plaintree Systems CEO David Watson, the future is inspired by the past.
How to build a winning sales team that gets your business off the ground by Jakob Wissel.
When Culture Matters by Bill Yeargin.

Follow the latest news live on CEOWORLD magazine and get news updates from the United States and around the world. The opinions expressed are those of the author and not necessarily those of CEOWORLD magazine.

Follow the headlines from CEOWORLD magazine on: Google News, LinkedIn, Twitterand Facebook.
Thank you for supporting our journalism. Subscribe here.

For media inquiries, please contact: info@ceoworld.biz